Concepedia

Kirk M. Chan‐Tack

KM

Statistics

Publications

20

Citations

1.5K

H-Index

16

Active since

1996

Affiliations

Johns Hopkins University(Current)

University of Maryland, Baltimore

Center for Drug Evaluation and Research

Johns Hopkins Hospital

National Institutes of Health

Kirk M. Chan‐Tack is an author at Johns Hopkins University specializing in medicine, infectious diseases, and virology.

ORCID

Publications per year

1996–2020

20

Publications

20

Endothelin-1 production and decreased endothelin B receptor expression in advanced prostate cancer.

J. Bradley Nelson, Kirk M. Chan‐Tack, Sean P. Hedican et al. · PubMed · 1996 · 333 citations

, , +13

FDA Approval of Remdesivir — A Step in the Right Direction

Daniel B. Rubin, Kirk M. Chan‐Tack, John Farley et al. · New England Journal of Medicine · 2020 · 224 citations · Full text

, , +13

E-cadherin expression as a marker of tumor aggressiveness in routinely processed radical prostatectomy specimens

Angelo M. De Marzo, Beatrice S. Knudsen, Kirk M. Chan‐Tack et al. · Urology · 1999 · 160 citations

, , +13

Phenylbutyrate induces apoptosis in human prostate cancer and is more potent than phenylacetate.

Michael A. Carducci, Joel B. Nelson, Kirk M. Chan‐Tack et al. · PubMed · 1996 · 148 citations

, , +10

Atazanavir-associated nephrolithiasis: cases from the US Food and Drug Administration's Adverse Event Reporting System

Kirk M. Chan‐Tack, Melissa M. Truffa, Kimberly Struble et al. · AIDS · 2007 · 117 citations

, , +17

1–5 of 20